Laromestrocel (Lomecel-B™)
Alzheimer’s Disease
Key Facts
About Longeveron
Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).
View full company profileAbout Longeveron
Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).
View full company profileAbout Longeveron
Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).
View full company profileAbout Longeveron
Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).
View full company profileAbout Longeveron
Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).
View full company profileTherapeutic Areas
Other Alzheimer’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| BMS-986446 (PRX005) | Prothena | Phase 1 |
| PRX019 | Prothena | Not Specified (Preclinical/Discovery) |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |